PGDx elio tissue complete
Apr 2020
267d
Personal Genome Diagnostics has submitted 1 FDA 510(k) premarket notifications since 2020, of which 1 received clearance as substantially equivalent to a predicate device.
The company's most frequent device categories include Next Generation Sequencing Based Tumor Profiling Test . Use the specialty filter in the sidebar to narrow results.